Shwu-Shin Chang1,2, Dan Eisenberg2,3, Lei Zhao1,2, Christopher Adams4, Ryan Leib4, John Morser1,2, Lawrence Leung1,2. 1. Division of Hematology, Stanford University School of Medicine, Stanford, California, USA. 2. Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA. 3. Department of Surgery, Stanford University School of Medicine, Stanford, California, USA. 4. Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, Stanford, California, USA.
Abstract
OBJECTIVE: Chemerin is an inflammatory adipokine, whose activity is regulated by successive proteolytic cleavages at its C-terminus. It is secreted as an inactive precursor (chem163S); cleavage at Lys158 converts it to chem158K with modest activity. Chem157S is the most potent form and chem155A is inactive. The aim of this study was to determine if chemerin was activated in samples from patients with obesity. METHODS: Using specific ELISAs for different chemerin forms and a pan-chemerin ELISA, chemerin forms in human obesity were characterized. RESULTS: Plasma chemerin from patients with obesity (BMI 44.3 ± 1.3 kg/m(2) , n = 29) was significantly higher than in lean controls (BMI 20.9 ± 0.7 kg/m(2) , n = 10) (160 ± 11 vs. 76.2 ± 5.5 ng/mL, respectively, P < 0.0001). This increase in chemerin was due to increased previously unattributed chemerin, with further C-terminal truncation demonstrated by mass spectrometry, accounting for ∼35% of total plasma chemerin. Chemerin forms in adipose tissue showed a different profile, with minimal chem163S and significant levels of chem157S. Chem155A was present in omental but not in subcutaneous adipose tissue. Unattributed chemerin forms were undetectable in adipose tissue. CONCLUSIONS: Chemerin is activated in adipose tissue of subjects with obesity, and further C-terminal processing occurs during the disposition of chemerin from adipose tissue, resulting in substantial levels of novel degraded forms in plasma that correlate with obesity.
OBJECTIVE:Chemerin is an inflammatory adipokine, whose activity is regulated by successive proteolytic cleavages at its C-terminus. It is secreted as an inactive precursor (chem163S); cleavage at Lys158 converts it to chem158K with modest activity. Chem157S is the most potent form and chem155A is inactive. The aim of this study was to determine if chemerin was activated in samples from patients with obesity. METHODS: Using specific ELISAs for different chemerin forms and a pan-chemerin ELISA, chemerin forms in humanobesity were characterized. RESULTS: Plasma chemerin from patients with obesity (BMI 44.3 ± 1.3 kg/m(2) , n = 29) was significantly higher than in lean controls (BMI 20.9 ± 0.7 kg/m(2) , n = 10) (160 ± 11 vs. 76.2 ± 5.5 ng/mL, respectively, P < 0.0001). This increase in chemerin was due to increased previously unattributed chemerin, with further C-terminal truncation demonstrated by mass spectrometry, accounting for ∼35% of total plasma chemerin. Chemerin forms in adipose tissue showed a different profile, with minimal chem163S and significant levels of chem157S. Chem155A was present in omental but not in subcutaneous adipose tissue. Unattributed chemerin forms were undetectable in adipose tissue. CONCLUSIONS:Chemerin is activated in adipose tissue of subjects with obesity, and further C-terminal processing occurs during the disposition of chemerin from adipose tissue, resulting in substantial levels of novel degraded forms in plasma that correlate with obesity.
Authors: Ali Momenpour; Patrícia D A Lima; Yi-An Chen; Chii-Ruey Tzeng; Benjamin K Tsang; Hanan Anis Journal: Biomed Opt Express Date: 2018-01-25 Impact factor: 3.732
Authors: Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink Journal: FASEB J Date: 2018-06-15 Impact factor: 5.191
Authors: Jay Toulany; Sebastian D Parlee; Christopher J Sinal; Kathryn Slayter; Shelly McNeil; Kerry B Goralski Journal: Endocr Connect Date: 2016-11-08 Impact factor: 3.335
Authors: Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis Journal: Int J Mol Sci Date: 2017-06-29 Impact factor: 5.923
Authors: Lei Zhao; Yasuto Yamaguchi; Xiaomei Ge; William H Robinson; John Morser; Lawrence L K Leung Journal: Arthritis Res Ther Date: 2018-07-04 Impact factor: 5.156
Authors: Xiaomei Ge; Yasuto Yamaguchi; Lei Zhao; Loredana Bury; Paolo Gresele; Caroline Berube; Lawrence L Leung; John Morser Journal: Blood Date: 2017-11-20 Impact factor: 25.476